Fig. 5: After surgery minimal residual disease (MRD) detection.
From: Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
a Swimmer plot illustrating the prospective clinical follow-up for the patients, indicating their treatments along with ctDNA/CTCs detection and clinical relapse status. b Detection of ctDNA (orange) and CTCs (red) in the post-surgery and follow-up blood samples (medians are illustrated as dashed lines and the upper and lower limits of the plots representing the maximum and minimum values, respectively). c Graphs show patients who experienced relapse, indicating the time in months from surgery to clinical relapse and MRD detection, as well as from MRD to clinical relapse. MRD minimal residual disease, ctDNA circulating tumor DNA, CTCs circulating tumor cells, NAC Neoadjuvant chemotherapy, FU Follow-up.
